Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Current Leases (2021 - 2025)

Capricor Therapeutics (CAPR) has 5 years of Current Leases data on record, last reported at $120094.0 in Q3 2025.

  • For Q3 2025, Current Leases fell 85.24% year-over-year to $120094.0; the TTM value through Sep 2025 reached $120094.0, down 85.24%, while the annual FY2024 figure was $834799.0, 11.44% up from the prior year.
  • Current Leases reached $120094.0 in Q3 2025 per CAPR's latest filing, down from $849505.0 in the prior quarter.
  • Across five years, Current Leases topped out at $849505.0 in Q2 2025 and bottomed at $120094.0 in Q3 2025.
  • Average Current Leases over 5 years is $673710.4, with a median of $718496.0 recorded in 2023.
  • Peak YoY movement for Current Leases: soared 63.31% in 2022, then plummeted 85.24% in 2025.
  • A 5-year view of Current Leases shows it stood at $417632.0 in 2021, then soared by 63.31% to $682039.0 in 2022, then grew by 9.83% to $749112.0 in 2023, then rose by 11.44% to $834799.0 in 2024, then tumbled by 85.61% to $120094.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $120094.0 in Q3 2025, $849505.0 in Q2 2025, and $842101.0 in Q1 2025.